​

CorMedix (CRMD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRMD Stock Forecast

CorMedix (CRMD) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $15.00, with a high of $15.00 and a low of $15.00. This represents a 82.93% increase from the last price of $8.20.

$6 $7 $8 $9 $10 $11 $12 $13 $14 $15 High: $15 Avg: $15 Low: $15 Last Closed Price: $8.2

CRMD Stock Rating

CorMedix stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

CRMD Price Target Upside V Benchmarks

TypeNameUpside
StockCorMedix82.93%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-16
Avg Price Target-$15.00$14.00
Last Closing Price$8.20$8.20$8.20
Upside/Downside-82.93%70.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2633---6
Sep, 2632---5
Aug, 2632---5
Jul, 2632---5
Jun, 2633---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 23, 2026Les SulewskiOppenheimer$15.00$7.7892.80%82.93%
Apr 28, 2026Leonid TimashevRBC Capital$14.00$7.8279.03%70.73%
Mar 06, 2026Roanna RuizLeerink Partners$13.00$6.46101.24%58.54%
Jan 23, 2026H.C. Wainwright$13.00$7.4474.73%58.54%
Jan 21, 2026RBC Capital$13.00$6.8888.95%58.54%
Jan 08, 2026Truist Financial$16.00$7.44115.05%95.12%
Oct 21, 2025Gregory RenzaRBC Capital$22.00$12.1680.92%168.29%
Aug 08, 2025Brandon FolkesH.C. Wainwright$17.00$10.3364.57%107.32%
Mar 13, 2024Gregory RenzaRBC Capital$9.00$3.90130.77%9.76%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 23, 2026OppenheimerOutperforminitialise
Apr 28, 2026RBC CapitalOutperformOutperformhold
Mar 06, 2026Leerink PartnersOutperformOutperformhold
Oct 21, 2025RBC CapitalOutperformOutperformhold
Aug 08, 2025H.C. WainwrightBuyBuyhold
Dec 19, 2024RBC CapitalOutperformOutperformhold
Aug 26, 2024Rodman & RenshawBuyinitialise
Aug 10, 2023RBC CapitalOutperforminitialise
Apr 25, 2022Zacks Investment ResearchSelldowngrade

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 $4 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.75$-0.74$-0.91$-0.30$2.25---
Avg Forecast$-0.80$-0.73$-0.85$-0.41$0.50$0.98$1.81$2.68
High Forecast$-0.68$-0.72$-0.78$-0.38$0.59$1.33$2.56$3.18
Low Forecast$-0.91$-0.75$-1.01$-0.49$0.46$0.74$0.99$2.46
Surprise %-6.25%1.37%7.06%-26.83%350.00%---

Revenue Forecast

$-50M $40M $130M $220M $310M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$190.94K$65.41K-$43.47M$311.71M---
Avg Forecast$124.33K$26.23K$-333.33K$39.55M$126.15M$161.46M$238.61M$330.20M
High Forecast$138.22K$26.63K$-312.64K$45.29M$144.46M$162.55M$240.51M$378.14M
Low Forecast$110.66K$25.94K$-381.72K$37.09M$118.32M$160.37M$236.71M$309.70M
Surprise %53.57%149.33%-9.92%147.09%---

Net Income Forecast

$-100M $-40M $20M $80M $140M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-28.21M$-29.70M$-46.34M$-17.93M$163.06M---
Avg Forecast$-40.55M$-37.19M$-46.34M$-22.00M$26.74M$52.56M$90.20M$136.17M
High Forecast$-34.76M$-36.66M$-39.77M$-19.19M$30.15M$67.68M$130.16M$161.86M
Low Forecast$-46.44M$-37.93M$-51.42M$-24.81M$23.32M$37.44M$50.25M$125.18M
Surprise %-30.44%-20.14%--18.49%509.86%---

CRMD Forecast FAQ

Is CorMedix stock a buy?

CorMedix stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that CorMedix is a favorable investment for most analysts.

What is CorMedix's price target?

CorMedix's price target, set by 8 Wall Street analysts, averages $15 over the next 12 months. The price target range spans from $15 at the low end to $15 at the high end, suggesting a potential 82.93% change from the previous closing price of $8.2.

How does CorMedix stock forecast compare to its benchmarks?

CorMedix's stock forecast shows a 82.93% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for CorMedix over the past three months?

  • October 2026: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 60.00% Strong Buy, 40.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 60.00% Strong Buy, 40.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is CorMedix’s EPS forecast?

CorMedix's average annual EPS forecast for its fiscal year ending in December 2026 is $0.98, marking a -56.44% decrease from the reported $2.25 in 2025. Estimates for the following years are $1.81 in 2027, and $2.68 in 2028.

What is CorMedix’s revenue forecast?

CorMedix's average annual revenue forecast for its fiscal year ending in December 2026 is $161.46M, reflecting a -48.20% decrease from the reported $311.71M in 2025. The forecast for 2027 is $238.61M, and $330.2M for 2028.

What is CorMedix’s net income forecast?

CorMedix's net income forecast for the fiscal year ending in December 2026 stands at $52.56M, representing a -67.77% decrease from the reported $163.06M in 2025. Projections indicate $90.2M in 2027, and $136.17M in 2028.